Last reviewed · How we verify
Human albumin
Human albumin is a Plasma volume expander; blood product derivative Small molecule drug developed by Hamad Medical Corporation. It is currently FDA-approved for Hypovolemic shock and acute blood loss, Severe hypoproteinemia and malnutrition, Burn management and fluid resuscitation. Also known as: Albumin infusion, Human-Albumin 20 % Behring, salzarm, albumin, Albumin.
Human albumin acts as a plasma volume expander and carrier protein that restores intravascular oncotic pressure and transports endogenous and exogenous substances throughout the body.
Human albumin is the most abundant protein in human blood plasma, making up about half of serum protein, and is produced in the liver. It is a protein-based sequestering agent that binds to bilirubin, a function that is utilized in various clinical trials for conditions such as Acute Respiratory Distress Syndrome and COVID-19 Pneumonia.
At a glance
| Generic name | Human albumin |
|---|---|
| Also known as | Albumin infusion, Human-Albumin 20 % Behring, salzarm, albumin, Albumin, Human Albumin 5% CSL Behring |
| Sponsor | Hamad Medical Corporation |
| Drug class | Plasma volume expander; blood product derivative |
| Modality | Small molecule |
| Therapeutic area | Critical Care; Hematology; Trauma |
| Phase | FDA-approved |
Mechanism of action
Human albumin is a naturally occurring serum protein that increases plasma colloid osmotic pressure, thereby drawing fluid from the interstitial space into the intravascular compartment to restore circulating blood volume. It also serves as a carrier protein for hormones, fatty acids, bilirubin, and drugs, facilitating their transport and distribution. This makes it useful in treating hypovolemia, shock, and conditions requiring plasma volume restoration or protein supplementation.
Approved indications
- Hypovolemic shock and acute blood loss
- Severe hypoproteinemia and malnutrition
- Burn management and fluid resuscitation
- Liver cirrhosis with ascites
- Nephrotic syndrome
Common side effects
- Hypervolemia and pulmonary edema
- Allergic reactions (rash, urticaria, anaphylaxis)
- Fever
- Chills
- Nausea
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (PHASE3)
- Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (PHASE2)
- Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy (NA)
- Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy (PHASE2)
- Study of DF1001 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human albumin CI brief — competitive landscape report
- Human albumin updates RSS · CI watch RSS
- Hamad Medical Corporation portfolio CI
Frequently asked questions about Human albumin
What is Human albumin?
How does Human albumin work?
What is Human albumin used for?
Who makes Human albumin?
Is Human albumin also known as anything else?
What drug class is Human albumin in?
What development phase is Human albumin in?
What are the side effects of Human albumin?
Related
- Drug class: All Plasma volume expander; blood product derivative drugs
- Manufacturer: Hamad Medical Corporation — full pipeline
- Therapeutic area: All drugs in Critical Care; Hematology; Trauma
- Indication: Drugs for Hypovolemic shock and acute blood loss
- Indication: Drugs for Severe hypoproteinemia and malnutrition
- Indication: Drugs for Burn management and fluid resuscitation
- Also known as: Albumin infusion, Human-Albumin 20 % Behring, salzarm, albumin, Albumin, Human Albumin 5% CSL Behring
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing